.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

EP. 1: Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

EP. 2: Dr Freedland on the Efficacy Results From the EMBARK Trial of Enzalutamide in Prostate Cancer

November 24th 2025

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

EP. 3: Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

EP. 4: Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

December 8th 2025

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.